61812-45-1

Upstream product

• 146857-81-0 4-methylthiobenzaldehyde 
• 32004-66-3 5-fluoro-2-methyl-1H-indene-3-acetic acid 
• 37794-19-7 6-fluoro-2-methylindanone 
• 53077-50-2 ethyl 2-(5-fluoro-2-methyl-1H-inden-3-yl)acetate 
• 3446-89-7 4-(Methylthio)benzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 
• 22138-73-4 3-(4-fluorophenyl)-2-methylpropanoic acid 
• 22138-72-3 3-(4-fluorophenyl)-2-methylacrylic acid 
• 37794-13-1 methyl 5-fluoro-2-methyl-1H-3-indenylacetate 
• 5137-55-3 Aliquat 336 

Downstream Products

• 38194-50-2 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetic acid 
• 38194-50-2 Sulindac 
• 53933-60-1 5-fluoro-2-methyl-1-(p-methylsulfinylbenzylidene)-3-indenyl acetic acid 

Relevant academic research and scientific papers

Green synthesis method of sulindac

The invention discloses a green synthesis method of sulindac and relates to the technical field of organic synthesis. The method comprises the following steps that: 6-fluoro-2-methyl indanone as a rawmaterial and cyanoacetic acid undergo a Knoevenagel reaction to obtain an intermediate 3, the intermediate 3 and p-methylthiobenzaldehyde undergo a Knoevenagel reaction to obtain an intermediate 4, the intermediate 4 undergoes a hydrolysis decarboxylation reaction to obtain an intermediate 5, and the intermediate 5 undergoes an oxidation reaction to obtain sulindac 1. Compared with an existing synthesis process, the process operation is greatly simplified, the raw material utilization rate and the process environmental protection property are improved, the total yield of sulindac reaches 80%or above, and the purity of sulindac reaches 99% or above.

METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY

Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols

Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of diabetic retinopathy.

Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols

Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of macular degeneration.

Method for treating patients with acne by administering a CGMP-specific PDE inhibitor

Inhibitors of cGMP-specific PDE are useful in the treatment of acne.

Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols

Substituted indenyl sulfonyl acetic acids, amides, and alcohols are useful in the treatment of acne.

Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols

Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of psoriasis.

Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols

Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of sarcoidosis.

Lactone compounds for treating patient with precancerous lesions

Substituted lactone compounds are useful in the treatment of precancerous lesions and neoplasms.

Esters and amides of substituted indenyl acetic acids

Esters and amides of substituted indenyl acetic acids of the formula: n is an integer of at least 2;, Q is a deprotonated residue of polymer or macromolecular structure having a molecular weight of at least about 1000 containing at least two primary and/or secondary amino groups and/or hydroxy groups;, R1 is selected from hydrogen, lower alkyl, or haloalkyl;, R2 is selected from hydrogen or alkyl;, R3 and R4 are one or more members each independently chosen from hydrogen, alkyl, acyloxy, alkoxy, nitro, amino, acylamino, alkylamino, diakylamino, dialkylaminoalkyl, sulfamyl, alkythio, mercapto, hydroxy, hydroxyalkyl, alkylsulfonyl, halogen, cyano, carboxyl, carbalkoxy, carbamido, haloalkyl or cycloalkoxy; and, R5 is selected from alkylsulfenyl, alkylsulfinyl or alkylsulfonyl. are useful in the treatment of colonic polyps.